'长新冠'：一项针对 COVID-19 住院后持续症状、生物标志物和影像学异常的横断面研究。
'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19.
机构信息
Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
Department of Radiology, Royal Free London NHS Foundation Trust, London, UK.
出版信息
Thorax. 2021 Apr;76(4):396-398. doi: 10.1136/thoraxjnl-2020-215818. Epub 2020 Nov 10.
Abstract
Large numbers of people are being discharged from hospital following COVID-19 without assessment of recovery. In 384 patients (mean age 59.9 years; 62% male) followed a median 54 days post discharge, 53% reported persistent breathlessness, 34% cough and 69% fatigue. 14.6% had depression. In those discharged with elevated biomarkers, 30.1% and 9.5% had persistently elevated d-dimer and C reactive protein, respectively. 38% of chest radiographs remained abnormal with 9% deteriorating. Systematic follow-up after hospitalisation with COVID-19 identifies the trajectory of physical and psychological symptom burden, recovery of blood biomarkers and imaging which could be used to inform the need for rehabilitation and/or further investigation.
摘要
大量 COVID-19 患者出院时并未进行康复评估。在中位随访时间为 54 天的 384 名患者中，53%报告持续呼吸困难，34%咳嗽，69%疲劳。14.6%有抑郁症状。出院时生物标志物升高的患者中，分别有 30.1%和 9.5%的人 d-二聚体和 C 反应蛋白持续升高。38%的胸部 X 线片仍异常，9%的患者恶化。对 COVID-19 住院患者进行系统随访，可以确定身体和心理症状负担、血液生物标志物和影像学恢复的轨迹，从而可以为康复和/或进一步检查提供依据。
相似文献
1
'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19.'长新冠'：一项针对 COVID-19 住院后持续症状、生物标志物和影像学异常的横断面研究。
Thorax. 2021 Apr;76(4):396-398. doi: 10.1136/thoraxjnl-2020-215818. Epub 2020 Nov 10.
2
Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study.新冠病毒感染后急性后遗症/新冠后综合征成年患者在急性感染后第二年的持续症状及临床发现：一项基于人群的巢式病例对照研究
PLoS Med. 2025 Jan 23;22(1):e1004511. doi: 10.1371/journal.pmed.1004511. eCollection 2025 Jan.
3
Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity.新冠后持续健康状况不佳与呼吸道并发症或初始疾病严重程度无关。
Ann Am Thorac Soc. 2021 Jun;18(6):997-1003. doi: 10.1513/AnnalsATS.202009-1175OC.
4
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.新冠肺炎出院患者 6 个月的后果：一项队列研究。
Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8.
5
Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study.COVID-19 住院幸存者 2 年后的健康结局：一项纵向队列研究。
Lancet Respir Med. 2022 Sep;10(9):863-876. doi: 10.1016/S2213-2600(22)00126-6. Epub 2022 May 11.
6
Patient-Reported Experiences of Persistent Post-COVID-19 Conditions After Hospital Discharge During the Second and Third Waves of the Pandemic in Switzerland: Cross-Sectional Questionnaire Study.瑞士第二波和第三波大流行期间出院后持续性 COVID-19 后患者报告的体验：横断面问卷调查研究。
JMIR Public Health Surveill. 2024 Aug 28;10:e47465. doi: 10.2196/47465.
7
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study.英国 COVID-19 住院患者多器官 MRI 研究（C-MORE）：一项前瞻性、多中心、观察性队列研究。
Lancet Respir Med. 2023 Nov;11(11):1003-1019. doi: 10.1016/S2213-2600(23)00262-X. Epub 2023 Sep 22.
8
Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2.常规实验室检测对预测 SARS-CoV-2 感染者死亡和病情恶化为重症或危重症 COVID-19 的准确性。
Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015050. doi: 10.1002/14651858.CD015050.pub2.
9
Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort.COVID-19 住院患者的预后及其随访意义：来自英国前瞻性队列研究的结果。
Thorax. 2021 Apr;76(4):399-401. doi: 10.1136/thoraxjnl-2020-216086. Epub 2020 Dec 3.
10
Serological Biomarkers in Individuals with Interstitial Lung Disease after SARS-CoV-2 Infection and Association with Post-COVID-19 Symptoms.新型冠状病毒感染后间质性肺疾病患者的血清生物标志物及其与新冠后遗症的关联
Pathogens. 2024 Jul 31;13(8):641. doi: 10.3390/pathogens13080641.
引用本文的文献
1
Breathless Aftermath: Post-COVID-19 Pulmonary Fibrosis.气喘吁吁的后果：新冠后肺纤维化
Viruses. 2025 Aug 9;17(8):1098. doi: 10.3390/v17081098.
2
Consensus based recommendations for the management of post-COVID long-term sequelae (Long COVID): a regional perspective.基于共识的新冠后长期后遗症（长新冠）管理建议：区域视角
Front Med (Lausanne). 2025 Aug 6;12:1453167. doi: 10.3389/fmed.2025.1453167. eCollection 2025.
3
The Use of Heart Rate Variability-Biofeedback (HRV-BF) as an Adjunctive Intervention in Chronic Fatigue Syndrome (CSF/ME) in Long COVID: Results of a Phase II Controlled Feasibility Trial.心率变异性生物反馈（HRV-BF）作为长期新冠慢性疲劳综合征（CSF/ME）辅助干预措施的应用：一项II期对照可行性试验的结果
J Clin Med. 2025 Jul 29;14(15):5363. doi: 10.3390/jcm14155363.
4
Follow-up evaluation of long COVID syndrome in patients with SARS-CoV-2 infection.新型冠状病毒肺炎（SARS-CoV-2）感染患者的长期新冠综合征随访评估
Rev Soc Bras Med Trop. 2025 Aug 8;58:e00462025. doi: 10.1590/0037-8682-0046-2025. eCollection 2025.
5
Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications.度匹非尼酮（LYT-100）用于治疗伴有呼吸并发症的新型冠状病毒肺炎急性后遗症。
ERJ Open Res. 2025 Jul 21;11(4). doi: 10.1183/23120541.01142-2024. eCollection 2025 Jul.
6
FeNO as a biomarker of interstitial and fibrotic pulmonary sequelae in patients admitted for severe SARS-CoV-2 pneumonia.呼出气一氧化氮作为重症新型冠状病毒肺炎患者间质性和纤维化肺部后遗症的生物标志物。
Sci Rep. 2025 Jul 16;15(1):25696. doi: 10.1038/s41598-025-09229-y.
7
Longitudinal Symptom Analysis of COVID-19 Survivors and Post-COVID Syndrome Patients.新冠康复者及新冠后综合征患者的纵向症状分析
Biomedicines. 2025 May 29;13(6):1334. doi: 10.3390/biomedicines13061334.
8
Dysregulated monocyte compartment in PACS patients.PACS患者中单核细胞区室失调。
Front Immunol. 2025 Jun 6;16:1613034. doi: 10.3389/fimmu.2025.1613034. eCollection 2025.
9
Advances in Understanding Long COVID: Pathophysiological Mechanisms and the Role of Omics Technologies in Biomarker Identification.长新冠理解的进展：病理生理机制及组学技术在生物标志物识别中的作用
Mol Diagn Ther. 2025 Jun 18. doi: 10.1007/s40291-025-00792-8.
10
IgA autoimmunity and coagulation among post-acute sequelae of SARS-CoV-2 infection (PASC) patients with persistent respiratory symptoms: a case-control study.新冠病毒感染后急性后遗症（PASC）患者持续呼吸道症状中的IgA自身免疫与凝血：一项病例对照研究
Front Immunol. 2025 May 30;16:1589559. doi: 10.3389/fimmu.2025.1589559. eCollection 2025.
本文引用的文献
1
Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation.COVID-19 感染幸存者出院后的症状和康复需求：一项横断面评估。
J Med Virol. 2021 Feb;93(2):1013-1022. doi: 10.1002/jmv.26368. Epub 2020 Aug 17.
2
Persistent Symptoms in Patients After Acute COVID-19.急性 COVID-19 后患者的持续症状。
JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.
3
Coagulopathy in COVID-19.新型冠状病毒疾病中的凝血功能障碍。
J Thromb Haemost. 2020 Sep;18(9):2103-2109. doi: 10.1111/jth.14975. Epub 2020 Jul 21.
4
Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge.出院后新型冠状病毒肺炎（COVID-19）患者的薄层 CT 分析。
J Xray Sci Technol. 2020;28(3):383-389. doi: 10.3233/XST-200685.
5
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.COVID-19 患者出院时的肺功能异常。
Eur Respir J. 2020 Jun 18;55(6). doi: 10.1183/13993003.01217-2020. Print 2020 Jun.
6
Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors.严重急性呼吸综合征（SARS）对一组幸存者肺功能、功能能力和生活质量的影响。
Thorax. 2005 May;60(5):401-9. doi: 10.1136/thx.2004.030205.
Zotero 插件